Generating local amyloidosis in mice by the subcutaneous injection of human insulin amyloid fibrils

Chinisaz,Maryam; Ebrahim-Habibi,Azadeh; Yaghmaei,Parichehreh; Parivar,Kazem; Dehpour,Ahmad-Reza

doi:10.3892/etm.2014.1772

Generating local amyloidosis in mice by the subcutaneous injection of human insulin amyloid fibrils

Authors:
- Maryam Chinisaz
- Azadeh Ebrahim-Habibi
- Parichehreh Yaghmaei
- Kazem Parivar
- Ahmad-Reza Dehpour
View Affiliations

Affiliations: Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran, Biosensor Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, Department of Pharmacology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Published online on: June 11, 2014 https://doi.org/10.3892/etm.2014.1772
Pages: 405-408

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Localized deposits of amyloid structures are observed in various pathological conditions. One example of when local amyloidosis occurs is following repeated insulin injections in diabetic patients. The present study aimed to simulate the same condition in mice. To obtain the amyloid structures, regular insulin was incubated at 57˚C for 24 h. The subsequently formed amyloid fibrils were analyzed using the Congo red absorbance test, as well as transmission electron microscopy images, and then injected into mice once per day for 21 consecutive days. Firm waxy masses were developed following this period, which were excised, prepared as thin sections and stained with hematoxylin and eosin, Congo red and Sudan black. Histological examination revealed that these masses contained adipose cells and connective tissue, in which amyloid deposition was visible. Thus, localized amyloidosis was obtained by the subcutaneous injection of insulin fibrils. The present results may be of further use in the development of models of amyloid tumors.

View Figures

View References

1	Husby G: Amyloidosis and rheumatoid arthritis. Clin Exp Rheumatol. 3:173–180. 1985.
2	Sahoo S, Reeves W and DeMay RM: Amyloid tumor: a clinical and cytomorphologic study. Diagn Cytopathol. 28:325–328. 2003. View Article : Google Scholar : PubMed/NCBI
3	Aono J, Yamagata K and Yoshida H: Local amyloidosis in the hard palate: a case report. Oral Maxillofac Surg. 13:119–122. 2009. View Article : Google Scholar : PubMed/NCBI
4	Weiss SW and Goldblum JR: Enzinger and Weiss’s Soft Tissue Tumors. 4th edition. Mosby Elsevier; Philadelphia, PA, USA: 2001
5	Krishnan J, Chu WS, Elrod JP and Frizzera G: Tumoral presentation of amyloidosis (amyloidomas) in soft tissues. A report of 14 cases. Am J Clin Pathol. 100:135–144. 1993.PubMed/NCBI
6	Khan SM, Birch PJ, Bass PS, Williams JH and Theaker JM: Localized amyloidosis of the lower genitourinary tract: a clinicopathological and immunohistochemical study of nine cases. Histopathology. 21:143–147. 1992. View Article : Google Scholar : PubMed/NCBI
7	Ihling C, Weirich G, Gaa A and Schaefer H: Amyloid tumors of the lung - an immunocytoma? Pathol Res Pract. 192:446–452. 1996. View Article : Google Scholar : PubMed/NCBI
8	Deans GT, Hale RJ, McMahon RF and Brough WA: Amyloid tumour of the colon. J Clin Pathol. 48:592–593. 1995. View Article : Google Scholar
9	Sie MP, van der Wiel HE, Smedts FM and de Boer AC: Human recombinant insulin and amyloidosis: an unexpected association. Neth J Med. 68:138–140. 2010.PubMed/NCBI
10	Dische FE, Wernstedt C, Westermark GT, Westermark P, Pepys MB, Rennie JA, Gilbey SG and Watkins PJ: Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia. 31:158–161. 1988. View Article : Google Scholar : PubMed/NCBI
11	Störkel S, Schneider HM, Müntefering H and Kashiwagi S: Iatrogenic, insulin-dependent, local amyloidosis. Lab Invest. 48:108–111. 1983.PubMed/NCBI
12	Swift B: Examination of insulin injection sites: an unexpected finding of localized amyloidosis. Diabet Med. 19:881–882. 2002. View Article : Google Scholar : PubMed/NCBI
13	Muzaffar M and Ahmad A: The mechanism of enhanced insulin amyloid fibril formation by NaCl is better explained by a conformational change model. PloS One. 6:e279062011. View Article : Google Scholar : PubMed/NCBI
14	Yumlu S, Barany R, Eriksson M and Röcken C: Localized insulin-derived amyloidosis in patients with diabetes mellitus: a case report. Hum Pathol. 40:1655–1660. 2009. View Article : Google Scholar : PubMed/NCBI
15	Albert SG, Obadiah J, Parseghian SA, Yadira Hurley M and Mooradian AD: Severe insulin resistance associated with subcutaneous amyloid deposition. Diabetes Res Clin Pract. 75:374–376. 2007. View Article : Google Scholar : PubMed/NCBI
16	Shikama Y, Kitazawa J, Yagihashi N, Uehara O, Murata Y, Yajima N, Wada R and Yagihashi S: Localized amyloidosis at the site of repeated insulin injection in a diabetic patient. Intern Med. 49:397–401. 2010. View Article : Google Scholar : PubMed/NCBI
17	El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, Bianchi E, Pessi A, Neill D and Wallace A: Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β-sheet and amyloid-like filaments. FEBS letters. 440:71–75. 1998.
18	Hertel C, Hauser N, Schubenel R, Seilheimer B and Kemp JA: β-amyloid-induced cell toxicity: enhancement of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-dependent cell death. J Neurochem. 67:272–276. 1996.
19	Meratan AA, Ghasemi A and Nemat-Gorgani M: Membrane integrity and amyloid cytotoxicity: a model study involving mitochondria and lysozyme fibrillation products. J Mol Biol. 409:826–838. 2011. View Article : Google Scholar
20	Maurice T, Lockhart BP and Privat A: Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction. Brain Res. 706:181–193. 1996.
21	Morimoto K, Yoshimi K, Tonohiro T, Yamada N, Oda T and Kaneko I: Co-injection of β-amyloid with ibotenic acid induces synergistic loss of rat hippocampal neurons. Neuroscience. 84:479–487. 1998.
22	Piermartiri TC, Vandresen-Filho S, de Araújo Herculano B, Martins WC, Dal’agnolo D, Stroeh E, Carqueja CL, Boeck CR and Tasca CI: Atorvastatin prevents hippocampal cell death due to quinolinic acid-induced seizures in mice by increasing Akt phosphorylation and glutamate uptake. Neurotox Res. 16:106–115. 2009. View Article : Google Scholar : PubMed/NCBI
23	Prediger RD, Franco JL, Pandolfo P, Medeiros R, Duarte FS, Di Giunta G, Figueiredo CP, Farina M, Calixto JB, Takahashi RN and Dafre AL: Differential susceptibility following β-amyloid peptide-(1–40) administration in C57BL/6 and Swiss albino mice: Evidence for a dissociation between cognitive deficits and the glutathione system response. Behav Brain Res. 177:205–213. 2007.
24	Klunk WE, Pettegrew J and Abraham DJ: Quantitative evaluation of congo red binding to amyloid-like proteins with a β-pleated sheet conformation. J Histochem Cytochem. 37:1273–1281. 1989.PubMed/NCBI
25	Wallymahmed ME, Littler P, Clegg C, Haqqani MT and Macfarlane IA: Nodules of fibrocollagenous scar tissue induced by subcutaneous insulin injections: a cause of poor diabetic control. Postgrad Med J. 80:732–733. 2004. View Article : Google Scholar : PubMed/NCBI
26	Westermark P, Araki S, Benson MD, Cohen AS, Frangione B, Masters CL, Saraiva MJ, Sipe JD, Husby G, Kyle RA and Selkoe D: Nomenclature of amyloid fibril proteins: Report from the meeting of the International Nomenclature Committee on Amyloidosis; August 8–9, 1998; Part 1: Amyloid. 6. pp. 63–66. 1999
27	Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ and Sipe JD: Amyloid fibril protein nomenclature - 2002. Amyloid. 9:197–200. 2002. View Article : Google Scholar : PubMed/NCBI
28	Cortés A: Primary cutaneous amyloidosis. Dermatologica. 139:109–114. 1969.
29	Kumar V, Abbas AK, Fausto N and Aster JC: Robbins and Cotran Pathologic Basis of Disease. 8th edition. Saunders Elsevier; Philadelphia, PA, USA: 2010
30	Rooban T, Saraswathi T, Al Zainab FH, Devi U, Eligabeth J and Ranganathan K: A light microscopic study of fibrosis involving muscle in oral submucous fibrosis. Indian J Dent Res. 16:131–134. 2005. View Article : Google Scholar : PubMed/NCBI
31	Lasagna-Reeves CA, Clos AL, Midoro-Hiriuti T, Goldblum RM, Jackson GR and Kayed R: Inhaled insulin forms toxic pulmonary amyloid aggregates. Endocrinology. 151:4717–4724. 2010. View Article : Google Scholar : PubMed/NCBI
32	Hazenberg BP, van Gameren II, Bijzet J, Jager PL and van Rijswijk MH: Diagnostic and therapeutic approach of systemic amyloidosis. Neth J Med. 62:121–128. 2004.PubMed/NCBI
33	Yamamoto T: Amyloidosis in the skin. Amyloidosis - an Insight to Disease of Systems and Novel Therapies. Güvenç IA: InTech; Rijecka, Croatia: pp. 91–104. 2011
34	Touart DM and Sau P: Cutaneous deposition diseases. Part I. J Am Acad Dermatol. 39:149–171. 1998. View Article : Google Scholar : PubMed/NCBI
35	Moon AO, Calamia KT and Walsh JS: Nodular amyloidosis: review and long-term follow-up of 16 cases. Arch Dermatol. 139:1157–1159. 2003.PubMed/NCBI
36	Truhan AP, Garden JM and Roenigk HH Jr: Nodular primary localized cutaneous amyloidosis: immunohistochemical evaluation and treatment with the carbon dioxide laser. J Am Acad Dermatol. 14:1058–1062. 1986. View Article : Google Scholar
37	Steciuk A, Dompmartin A, Troussard X, Verneuil L, Macro M, Comoz F and Leroy D: Cutaneous amyloidosis and possible association with systemic amyloidosis. Int J Dermatol. 41:127–132. 2002. View Article : Google Scholar : PubMed/NCBI
38	Woollons A and Black MM: Nodular localized primary cutaneous amyloidosis: a long-term follow-up study. Br J Dermatol. 145:105–109. 2001. View Article : Google Scholar : PubMed/NCBI